Related Organizations
Articles from this author
August 14, 2026
A massive human genetics study identified rare folliculin-interacting protein 1 (FNIP1) mutations associated with favorable metabolism and much lower cardiometabolic disease risk. Experiments in human liver cells and mice suggest a therapeutic route [1]. Longevity hidden in the genome For decades, aging researchers have hoped that human genetics might reveal genuine “longevity genes” whose altered...
August 11, 2026
A new study proposes a theoretical framework that explains why the more complex an animal is, the harder it is to move the needle on its rate of aging [1]. A problem of great complexity A familiar puzzle in geroscience is that while many of the same longevity-related pathways are highly evolutionarily conserved, manipulating them...
August 07, 2026
Human Longevity Inc., a company founded in 2013 by a trio of visionaries – Craig Venter, Peter Diamandis, and Robert Hariri – initially inspired high hopes. Several years and several hundred million dollars later, however, the company entered what many people saw as a period of turmoil. Dr. Wei-Wu He, an early investor in HLI,...
August 04, 2026
A new study has found that restricting dietary valine extends both median and maximum lifespan in male mice while improving healthspan in both sexes. The mechanism remains unclear, though increased liver mitochondrial activity emerged as a leading clue. Protein composition matters The debates around how much protein people should consume to maximize their healthspan and...
July 31, 2026
For the last several years, Dr. José Pedro Castro, a Gladyshev Lab alumnus, who is now Assistant Researcher and Project Principal Investigator at the Institute for Research and Innovation in Health at the University of Porto, has been studying inflammation and its crucial role in aging and disease. Earlier this month, he received the Rising...
July 28, 2026
Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity field will tell you that regulation is holding it back. Sensible oversight of novel therapies is essential, but an overly cautious interpretation of...